AmVac's Vaccine against RSV Attains Next Milestone
RSV (Respiratory Syncytial Virus) is one of the most common causes of bronchiolitis and pneumonia and a leading cause of childhood hospitalization around the world. The disease is particularly dangerous and potentially life-threatening for premature babies, children with other health conditions and the elderly. A high-cost monoclonal antibody therapy with limited efficacy is currently the only specific treatment option.
AmVac's vaccine candidate AMV602 is based on an innovative technology (Sendai vector technology) that was invented at the Max Planck Institute for Biochemistry, Martinsried, Germany and developed by AmVac.
In preclinical studies, renowned RSV expert Prof.ssa Grazia Cusi and her team at the University of Siena, Italy, have now confirmed the candidate's excellent safety and efficacy, showing that even reduced doses of AMV602 trigger effective immune protection against RSV. Moreover, they have significantly expanded the database concerning the vaccine's therapeutic mode of action. A detailed analysis of immunological parameters further substantiates its exceptional ability to activate the two mechanisms of immune defense at the same time: the humoral immune response with antibodies as key players, and the cellular immune response with macrophages, natural killer cells and specific cytotoxic T cells as effectors.
AmVac AG, founded in 2005, is a biopharmaceutical company that develops and markets innovative vaccines. With headquarters in Switzerland, research laboratories in Germany and Italy and a production facility in Hungary, the company brings together leading European experts in the field.
Profitable investment in Swiss start-ups
Acquisitions are extremely important for the Swiss start-up scene; they show that investment in young companies is worthwhile and they can help to improve the supply of venture capital. And in the last week we reported about several acquisitions:Yield Pop, Sensima Technology, Sight.IO, and Covagen.